Pulmonx (NASDAQ:LUNG – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.
Volatility and Risk
Pulmonx has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Assure has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
Institutional & Insider Ownership
88.1% of Pulmonx shares are owned by institutional investors. Comparatively, 21.8% of Assure shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 28.1% of Assure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pulmonx presently has a consensus target price of $15.00, suggesting a potential upside of 47.49%. Assure has a consensus target price of $25.33, suggesting a potential upside of 9,145.74%. Given Assure’s stronger consensus rating and higher possible upside, analysts plainly believe Assure is more favorable than Pulmonx.
Earnings and Valuation
This table compares Pulmonx and Assure’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pulmonx||$53.66 million||7.21||-$58.92 million||($1.61)||-6.32|
|Assure||$9.73 million||0.15||-$30.11 million||N/A||N/A|
Assure has lower revenue, but higher earnings than Pulmonx.
This table compares Pulmonx and Assure’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.
Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.